Athenex, Inc. (ATNX): Price and Financial Metrics
GET POWR RATINGS... FREE!
ATNX POWR Grades
- ATNX scores best on the Growth dimension, with a Growth rank ahead of 97.41% of US stocks.
- ATNX's strongest trending metric is Growth; it's been moving up over the last 71 days.
- ATNX ranks lowest in Quality; there it ranks in the 3rd percentile.
ATNX Stock Summary
- ATNX's price/sales ratio is 0.26; that's higher than the P/S ratio of merely 7.16% of US stocks.
- In terms of volatility of its share price, ATNX is more volatile than 93.11% of stocks we're observing.
- ATHENEX INC's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is 17.9%, greater than the shareholder yield of 90.82% of stocks in our set.
- Stocks with similar financial metrics, market capitalization, and price volatility to ATHENEX INC are SNCR, OPGN, SPOK, ACIW, and LGHL.
- Visit ATNX's SEC page to see the company's official filings. To visit the company's web site, go to www.athenex.com.
ATNX Valuation Summary
- ATNX's price/sales ratio is 0.3; this is 85% lower than that of the median Healthcare stock.
- Over the past 67 months, ATNX's price/sales ratio has gone down 33.5.
Below are key valuation metrics over time for ATNX.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| ATNX | 2022-12-02 | 0.3 | 1.3 | -0.2 | -0.7 |
| ATNX | 2022-12-01 | 0.3 | 1.3 | -0.2 | -0.7 |
| ATNX | 2022-11-30 | 0.3 | 1.3 | -0.2 | -0.8 |
| ATNX | 2022-11-29 | 0.2 | 1.1 | -0.2 | -0.7 |
| ATNX | 2022-11-28 | 0.2 | 1.1 | -0.2 | -0.7 |
| ATNX | 2022-11-25 | 0.2 | 1.1 | -0.2 | -0.7 |
ATNX's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- ATNX has a Quality Grade of F, ranking ahead of 2.45% of graded US stocks.
- ATNX's asset turnover comes in at 0.31 -- ranking 148th of 681 Pharmaceutical Products stocks.
- XNCR, DRRX, and VRTX are the stocks whose asset turnover ratios are most correlated with ATNX.
The table below shows ATNX's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.310 | 0.344 | -0.445 |
| 2021-03-31 | 0.384 | 0.334 | -0.479 |
| 2020-12-31 | 0.416 | 0.340 | -0.548 |
| 2020-09-30 | 0.477 | 0.409 | -0.574 |
| 2020-06-30 | 0.472 | 0.394 | -0.716 |
| 2020-03-31 | 0.404 | 0.436 | -0.726 |
ATNX Price Target
For more insight on analysts targets of ATNX, see our ATNX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $9.17 | Average Broker Recommendation | 1.71 (Moderate Buy) |
ATNX Stock Price Chart Interactive Chart >
ATNX Price/Volume Stats
| Current price | $0.18 | 52-week high | $1.74 |
| Prev. close | $0.18 | 52-week low | $0.16 |
| Day low | $0.17 | Volume | 762,839 |
| Day high | $0.19 | Avg. volume | 1,272,719 |
| 50-day MA | $0.21 | Dividend yield | N/A |
| 200-day MA | $0.51 | Market Cap | 27.99M |
Athenex, Inc. (ATNX) Company Bio
Athenex Inc. is a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer. The company was founded in 2003 and is based in Buffalo, New York.
Latest ATNX News From Around the Web
Below are the latest news stories about ATHENEX INC that investors may wish to consider to help them evaluate ATNX as an investment opportunity.
Athenex Announces Positive Results of Special Stockholder MeetingShareholders voted in favor of all three proposals submitted before the Special Stockholder Meeting BUFFALO, N.Y., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced the results of its special meeting of stockholders (the “Special Meeting”), held as a virtual meeting on November 22, 2022. Athenex sha |
Athenex Announces Closing of the Sale of its China API BusinessBUFFALO, N.Y., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced the closing of the sale of its equity interests in its China subsidiaries, which primarily represent the Company’s ownership of its active pharmaceutical ingredient (API) manufacturing business in China, to Chongqing Comfort Pharmaceut |
Athenex Third Quarter 2022 Earnings: Beats ExpectationsAthenex ( NASDAQ:ATNX ) Third Quarter 2022 Results Key Financial Results Revenue: US$33.5m (up 6.7% from 3Q 2021). Net... |
Athenex to Participate in the 5th Annual Evercore ISI HealthCONx ConferenceBUFFALO, N.Y., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Athenex (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that management will participate in the 5th Annual Evercore ISI HealthCONx Conference, taking place virtually November 29 to December 1, 2022. Dr. Johnson Lau, Chief Executive Officer of Athenex, and Dr. Dan Lang, President of Athenex Cell Th |
Athenex, Inc. (ATNX) CEO Johnson Lau on Q3 2022 Results - Earnings Call TranscriptAthenex, Inc. (ATNX) Q3 2022 Earnings Conference Call November 03, 2022 08:00 AM ET Company Participants Tim McCarthy - MD, Investor Relations Johnson Lau - Chief Executive Officer Dan Lang - President, Athenex Cell Therapy Darrel Cohen - Chief Medical Officer, Cell Therapy Jeff Yordon - Chief Operating Officer Joe Annoni - Chief Financial Officer Conference Call Participants Jon Miller - Evercore Yale Jen - Laidlaw & Co Presentation Operator Good day, ladies and gentlemen and welcome to the Athenex Third Quarter 2022 Earnings Conference Call. [Operator Instructions] I would now like to hand the conference over to Tim McCart... |
ATNX Price Returns
| 1-mo | -9.91% |
| 3-mo | -59.09% |
| 6-mo | -64.01% |
| 1-year | -89.22% |
| 3-year | -98.99% |
| 5-year | -98.87% |
| YTD | -86.76% |
| 2021 | -87.70% |
| 2020 | -27.57% |
| 2019 | 20.33% |
| 2018 | -20.19% |
| 2017 | N/A |
Continue Researching ATNX
Want to do more research on Athenex Inc's stock and its price? Try the links below:Athenex Inc (ATNX) Stock Price | Nasdaq
Athenex Inc (ATNX) Stock Quote, History and News - Yahoo Finance
Athenex Inc (ATNX) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...